Related Experiment Videos

Randomized controlled trial of Tinospora crispa for additional therapy in patients with type 2 diabetes mellitus

Chawanya Sangsuwan1, Suthipol Udompanthurak, Sathit Vannasaeng

  • 1Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Journal of the Medical Association of Thailand = Chotmaihet Thangphaet
|June 30, 2004
PubMed

Insights

Tinospora crispa did not improve blood sugar control in type 2 diabetes patients. This herbal supplement showed no benefits and may pose a risk of liver dysfunction.

Area of Science:

  • Herbal medicine research
  • Endocrinology
  • Clinical pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) affects millions globally.
  • Management of T2DM often requires multifaceted approaches.
  • Patients unresponsive to oral hypoglycemic drugs (OHDs) present a clinical challenge.

Purpose of the Study:

  • To evaluate Tinospora crispa as an adjunct therapy for T2DM.
  • To assess its efficacy in patients refractory to OHDs and unwilling to use insulin.
  • To investigate the impact on glycemic control and metabolic parameters.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial.
  • Twenty patients received Tinospora crispa (1g thrice daily) for 6 months.
  • Twenty patients received a placebo; outcomes included fasting plasma glucose, HbA1c, and insulin levels.

Main Results:

  • No significant changes in fasting plasma glucose, HbA1c, or insulin levels were observed.
  • Two patients on Tinospora crispa experienced elevated liver enzymes, resolving upon discontinuation.
  • Tinospora crispa group showed weight reduction and cholesterol elevation.

Conclusions:

  • Tinospora crispa at 3 grams daily is not supported as an additional therapy for T2DM.
  • Evidence does not support its use in patients unresponsive to OHDs.
  • Potential risk of hepatic dysfunction associated with Tinospora crispa use.

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...